Thrombophilia of neprhotic syndrome in adults

Clinical Advances in Hematology and Oncology

Volumn 7, Issue 6, 2009, Pages 368-372

  Bramham, Kate ^a   Hunt, Beverly J ^b   Goldsmith, David ^c  

^a Biomedical Research Centre   (United Kingdom)

^b Department of Thrombosis and Haemostasis ^*  (United Kingdom)

^c GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVITAMIN K; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; PRAVASTATIN; ANTICOAGULANT AGENT; BLOOD CLOTTING FACTOR;

ADULT; ARTERY THROMBOSIS; ARTICLE; BLEEDING; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG MEGADOSE; DRUG SAFETY; ENDOTHELIAL DYSFUNCTION; FIBRINOLYSIS; HIGH RISK PATIENT; HUMAN; HYPERCHOLESTEROLEMIA; KIDNEY VEIN THROMBOSIS; LUNG ANGIOGRAPHY; LUNG EMBOLISM; MECHANICAL THROMBECTOMY; MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS; MEMBRANOUS GLOMERULONEPHRITIS; NEPHROTIC SYNDROME; PATIENT ASSESSMENT; RISK ASSESSMENT; THROMBOCYTE FUNCTION; THROMBOPHILIA; THROMBOSIS PREVENTION; VENOUS THROMBOEMBOLISM; ANTITHROMBIN III DEFICIENCY; BLOOD; CHILD; METABOLISM; PATHOPHYSIOLOGY; REVIEW; RISK; THROMBOCYTE ACTIVATION; THROMBOSIS; VASCULAR ENDOTHELIUM;

ADULT; ANTICOAGULANTS; ANTITHROMBIN III DEFICIENCY; BLOOD COAGULATION FACTORS; CHILD; ENDOTHELIUM, VASCULAR; HUMANS; NEPHROTIC SYNDROME; PLATELET ACTIVATION; RISK; THROMBOPHILIA; THROMBOSIS;

EID: 70349510436     PISSN: 15430790     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (72)

1. Kleyman TR, Hughey RP. Plasmin and sodium retention in nephrotic syndrome. J Am Soc Nephrol. 2009;20:233-234.
2. Korbet SM, Genchi RM, Borok RZ, Schwartz MM. The racial prevalence of glomerular lesions in nephrotic adults. Am J Kidney Dis. 1996;27:647-651.
3. Singhal R, Brimble KS. Thromboembolic complications in the nephrotic syndrome: pathophysiology and clinical management. Thromb Res. 2006;118:397-407.
4. Llach F. Hypercoagulability, renal vein thrombosis, and other thrombotic complications of nephrotic syndrome. Kidney Int. 1985;28:429-439.
5. Glassock RJ. Prophylactic anticoagulation in nephrotic syndrome: a clinical conundrum. J Am Soc Nephrol. 2007;18:2221-2225.
6. Llach F, Papper S, Massry SG. The clinical spectrum of renal vein thrombosis: acute and chronic. Am J Med. 1980;69:819-827.
7. Cheng S.C. HWS, Wang Y.F., Yang S.P., Lin Y.F. The role of lung scintigraphy in the diagnosis of nephrotic syndrome with pulmonary embolism Clin Nucl Med. 2000;25:167-172.
8. Kayali F, Najjar R, Aswad F, Matta F, Stein PD. Venous thromboembolism in patients hospitalized with nephrotic syndrome. Am J Med. 2008;121:226-230.
9. Mahmoodi BK, ten Kate MK, Waanders F, et al. High absolute risks and predictors of venous and arterial thromboembolic events in patients with nephrotic syndrome: results from a large retrospective cohort study. Circulation. 2008;117:224-230.
10. Wakui H, Imai H, Komatsuda A, Miura AB. Circulating antibodies against alpha-enolase in patients with primary membranous nephropathy (MN). Clin Exp Immunol. 1999;118:445-450.
11. Irish AB. The factor V Leiden mutation and risk of renal vein thrombosis in patients with nephrotic syndrome. Nephrol Dial Transplant. 1997;12:1680-1683.
12. Wass VJ, Jarrett RJ, Chilvers C, Cameron JS. Does the nephrotic syndrome increase the risk of cardiovascular disease? Lancet. 1979;2:664-667.
13. Ordonez JD, Hiatt RA, Killebrew EJ, Fireman BH. The increased risk of coronary heart disease associated with nephrotic syndrome. Kidney Int. 1993;44:638-642.
14. Bellomo R, Atkins RC. Membranous nephropathy and thromboembolism: is prophylactic anticoagulation warranted? Nephron. 1993;63:249-254.
15. Bellomo R, Wood C, Wagner I, et al. Idiopathic membranous nephropathy in an Australian population: the incidence of thromboembolism and its impact on the natural history. Nephron. 1993;63:240-241.
16. Llach F, Arieff AI, Massry SG. Renal vein thrombosis and nephrotic syndrome. A prospective study of 36 adult patients. Ann Intern Med 1975;83:8-14.
17. Llach F, Koffler A, Finck E, Massry SG. On the incidence of renal vein thrombosis in the nephrotic syndrome. Arch Intern Med. 1977;137:333-336.
18. Sarasin FP, Schifferli JA. Prophylactic oral anticoagulation in nephrotic patients with idiopathic membranous nephropathy. Kidney Int. 1994;45:578-585.
19. Grau E, Oliver A, Felez J, et al. Plasma and urinary heparin cofactor II levels in patients with nephrotic syndrome. Thromb Haemost. 1988;60:137-140.
20. Kauffmann RH, Veltkamp JJ, Van Tilburg NH, Van Es LA. Acquired anti-thrombin III deficiency and thrombosis in the nephrotic syndrome. Am J Med. 1978;65:607-613.
21. Kanfer A, Kleinknecht D, Broyer M, Josso F. Coagulation studies in 45 cases of nephrotic syndrome without uremia. Thromb Diath Haemorrh. 1970;24:562-571.
22. Cosio FG, Harker C, Batard MA, Brandt JT, Griffin JH. Plasma concentrations of the natural anticoagulants protein C and protein S in patients with proteinuria. J Lab Clin Med. 1985;106:218-222.
23. Thomson C, Forbes CD, Prentice CR, Kennedy AC. Changes in blood coagulation and fibrinolysis in the nephrotic syndrome. Q J Med. 1974;43:399-407.
24. Thaler E, Balzar E, Kopsa H, Pinggera WF. Acquired antithrombin III deficiency in patients with glomerular proteinuria. Haemostasis. 1978;7:257-272.
25. Hoyer PF, Gonda S, Barthels M, Krohn HP, Brodehl J. Thromboembolic complications in children with nephrotic syndrome. Risk and incidence. Acta Paediatr Scand. 1986;75:804-810.
26. Robert A, Olmer M, Sampol J, Gugliotta JE, Casanova P. Clinical correlation between hypercoagulability and thrombo-embolic phenomena. Kidney Int. 1987;31:830-835.
27. de Sain-van der Velden MG, Rabelink TJ, Reijngoud DJ, et al. Plasma alpha 2 macroglobulin is increased in nephrotic patients as a result of increased synthesis alone. Kidney Int. 1998;54:530-535.
28. Goulault-Heilmann M. G-PT, Levelnt M., Intrator L., Rostoler G., Lagrue G. Total and free protein S in nephrotic syndrome. Thromb Res. 1988;49:37-42.
29. Vigano-D'Angelo S, D'Angelo A, Kaufman CE, Jr., Sholer C, Esmon CT, Comp PC. Protein S deficiency occurs in the nephrotic syndrome. Ann Intern Med. 1987;107:42-47.
30. Epstein O, Bevan G, Siddiqui N, Ardeman S. Factor VII deficiency associated with nephrotic syndrome. Br Med J. 1976;2:1361.
31. Vaziri ND, Ngo JL, Ibsen KH, Mahalwas K, Roy S, Hung EK. Deficiency and urinary losses of factor XII in adult nephrotic syndrome. Nephron. 1982;32:342-346.
32. Cameron JS. The nephrotic syndrome and its complications. Am J Kidney Dis. 1987;10:157-171.
33. Cameron JS. Coagulation and thromboembolic complications in the nephrotic syndrome. Adv Nephrol Necker Hosp. 1984;13:75-114.
34. Kanfer A. Coagulation factors in nephrotic syndrome. Am J Nephrol. 1990;10 Suppl 1:63-68.
35. Kendall AG, Lohmann RC, Dossetor JB. Nephrotic syndrome. A hypercoagulable state. Arch Intern Med. 1971;127:1021-1027.
36. Al-Mugeiren MM, Abdel Gader AG, Al-Rasheed SA, Al-Salloum AA. Tissue factor pathway inhibitor in childhood nephrotic syndrome. Pediatr Nephrol. 2006;21:771-777.
37. Ariens RA, Moia M, Rivolta E, Ponticelli C, Mannucci PM. High levels of tissue factor pathway inhibitor in patients with nephrotic proteinuria. Thromb Haemost. 1999;82:1020-1023.
38. Dogra GK, Herrmann S, Irish AB, Thomas MA, Watts GF. Insulin resistance, dyslipidaemia, inflammation and endothelial function in nephrotic syndrome. Nephrol Dial Transplant. 2002;17:2220-2225.
39. Ece A, Atamer Y, Gurkan F, Bilici M, Kocyigit Y. Anti-oxidant status in relation to lipoproteins, leptin and pro-inflammatory cytokines in children with steroid-sensitive nephrotic syndrome. Nephrology (Carlton). 2004;9:366-373.
40. Takeda Y, Chen AY. Fibrinogen metabolism and distribution in patients with the nephrotic syndrome. J Lab Clin Med. 1967;70:678-685.
41. Zwaginga JJ, Koomans HA, Sixma JJ, Rabelink TJ. Thrombus formation and platelet-vessel wall interaction in the nephrotic syndrome under flow conditions. J Clin Invest. 1994;93:204-211.
42. Winter CS, Wagoner R.D., Bowie E.J.W., Owen C.A. Dysfibrinogenemia and hypercoagulability in patients with membranous nephropathy (Abstract). Thronb Haemost. 1979;42:67.
43. Sagripanti A, Cupisti A, Baicchi U, Ferdeghini M, Barsotti G. In vivo measurements of fibrin formation and degradation in nephrotic patients. Int J Clin Lab Res. 1994;24:113-116.
44. Tomura S, Ideura T, Ida T, et al. Renal vein fibrin degradation products (FDP's) in glomerulonephritis. Clin Nephrol. 1979;12:248-253.
45. Edward N, Young DP, Macleod M. Fibrinolytic Activity in Plasma and Urine in Chronic Renal Disease. J Clin Pathol. 1964;17:365-368.
46. Wu KK, Hoak JC. Urinary plasminogen and chronic glomerulonephritis. Am J Clin Pathol. 1973;60:915-919.
47. Du XH, Glas-Greenwalt P, Kant KS, Allen CM, Hayes S, Pollak VE. Nephrotic syndrome with renal vein thrombosis: pathogenetic importance of a plasmin inhibitor (alpha 2-antiplasmin). Clin Nephrol. 1985;24:186-191.
48. Yoshida Y, Shiiki H, Iwano M, et al. Enhanced expression of plasminogen activator inhibitor 1 in patients with nephrotic syndrome. Nephron. 2001;88:24-29.
49. Gandrille S. AM. Alubin concentration influences fibrinolytic activity in plasma and purified systems. Fibrinolysis. 1990;4:225-232.
50. Boneu B, Bouissou F, Abbal M, Sie P, Caranobe C, Barthe P. Comparison of progressive antithrombin activity and the concentration of three thrombin inhibitors in nephrotic syndrome. Thromb Haemost. 1981;46:623-625.
51. Bang NU, Trygstad W, Schroeder JE, Heidenreich RO, Csiscko BM. Enhanced platelet function in glomerular renal disease. J Lab Clin Med. 1973;81:651-660.
52. Remuzzi G, Mecca G, Marchesi D, et al. Platelet hyperaggregability and the nephrotic syndrome. Thromb Res. 1979;16:345-354.
53. Tomura S, Ida T, Kuriyama R, et al. Activation of platelets in patients with chronic proliferative glomerulonephritis and the nephrotic syndrome. Clin Nephrol. 1982;17:24-30.
54. Machleidt C, Mettang T, Starz E, Weber J, Risler T, Kuhlmann U. Multifactorial genesis of enhanced platelet aggregability in patients with nephrotic syndrome. Kidney Int. 1989;36:1119-1124.
55. Rabelink AJ, Hene RJ, Erkelens DW, Joles JA, Koomans HA. Effects of simvastatin and cholestyramine on lipoprotein profile in hyperlipidaemia of nephrotic syndrome. Lancet. 1988;2:1335-1338.
56. Taira K, Kamitsuji H, Okajima C, Fujimura Y. Enhanced ristocetin-induced von Willebrand factor binding to platelet glycoprotein Ib in patients with steroid-responsive nephrotic syndrome. Haemostasis. 1990;20:219-228.
57. Sirolli V, Ballone E, Garofalo D, et al. Platelet activation markers in patients with nephrotic syndrome. A comparative study of different platelet function tests. Nephron. 2002;91:424-430.
58. Adler AJ, Lundin AP, Feinroth MV, Friedman EA, Berlyne GM. Beta-thromboglobulin levels in the nephrotic syndrome. Am J Med. 1980;69:551-554.
59. Yoshida N, Aoki N. Release of arachidonic acid from human platelets. A key role for the potentiation of platelet aggregability in normal subjects as well as in those with nephrotic syndrome. Blood. 1978;52:969-977.
60. Jackson CA, Greaves M, Patterson AD, Brown CB, Preston FE. Relationship between platelet aggregation, thromboxane synthesis and albumin concentration in nephrotic syndrome. Br J Haematol. 1982;52:69-77.
61. Stroes ES, Joles JA, Chang PC, Koomans HA, Rabelink TJ. Impaired endothelial function in patients with nephrotic range proteinuria. Kidney Int. 1995;48:544-550.
62. Watts GF, Herrmann S, Dogra GK, et al. Vascular function of the peripheral circulation in patients with nephrosis. Kidney Int. 2001;60:182-189.
63. Joles JA, Stroes ES, Rabelink TJ. Endothelial function in proteinuric renal disease. Kidney Int Suppl. 1999;71:S57-S61.
64. Dogra G, Irish AB, Watts GF. Homocysteine and nephrotic syndrome. Nephrol Dial Transplant. 2001;16:1720-1721.
65. Pickart L. Increased ratio of plasma free fatty acids to albumin during normal aging and in patients with coronary heart disease. Atherosclerosis. 1983;46:21-28.
66. Rostoker G, Durand-Zaleski I, Petit-Phar M, et al. Prevention of thrombotic complications of the nephrotic syndrome by the low-molecular-weight heparin enoxaparin. Nephron. 1995;69:20-28.
67. Vermylen CG, Levin M, Lanham JG, Hardisty RM, Barratt TM. Decreased sensitivity to heparin in vitro in steroid-responsive nephrotic syndrome. Kidney Int. 1987;31:1396-1401.
68. Briefel GR, Manis T, Gordon DH, Nicastri AD, Friedman EA. Recurrent renal vein thrombosis consequent to membranous glomerulonephritis. Clin Nephrol. 1978;10:32-37.
69. Falga C, Capdevila JA, Soler S, et al. Clinical outcome of patients with venous thromboembolism and renal insufficiency. Findings from the RIETE registry. Thromb Haemost. 2007;98:771-776.
70. Charlesworth JA, Gracey DM, Pussell BA. Adult nephrotic syndrome: non-specific strategies for treatment. Nephrology (Carlton). 2008;13:45-50.
71. Yashiro M, Muso E, Shio H, Sasayama S. Amelioration of hypercholesterolaemia by HMG-CoA reductase inhibitor (Pravastatin) improved platelet hyperaggregability in nephrotic patients. Nephrol Dial Transplant. 1994;9:1842-1843.
72. Mehls O, Andrassy K, Koderisch J, Herzog U, Ritz E. Hemostasis and thromboembolism in children with nephrotic syndrome: differences from adults. J Pediatr. 1987;110:862-867.